Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

S.R. Skinner; A. Szarewski; B. Romanowski; S.M. Garland; E. Lazcano-Ponce; J. Salmerón; M.R. del Rosario-Raymundo; R.H.M. Verheijen; S.C. Quek; D.P. da Silva; H. Kitchener; K.L. Fong; C. Bouchard; D.M. Money; A. Illancheran; M.E. Cruickshank; M.J. Levin; A. Chatterjee; J.T. Stapleton; W. Quint; M.P. David; D. Meric; K. Hardt; D. Descamps; B. Geeraerts; F. Struyf; G. Dubin

doi:10.10116

Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Translated title of the contribution: Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

S.R. Skinner, A. Szarewski, B. Romanowski, S.M. Garland, E. Lazcano-Ponce, J. Salmerón, M.R. del Rosario-Raymundo, R.H.M. Verheijen, S.C. Quek, D.P. da Silva, H. Kitchener, K.L. Fong, C. Bouchard, D.M. Money, A. Illancheran, M.E. Cruickshank, M.J. Levin, A. Chatterjee, J.T. Stapleton, W. QuintM.P. David, D. Meric, K. Hardt, D. Descamps, B. Geeraerts, F. Struyf, G. Dubin

Cancer

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Original language	Undefined/Unknown
Pages (from-to)	2213-2227
Number of pages	15
Journal	The Lancet
Volume	384
DOIs	https://doi.org/10.10116
Publication status	Published - 2014

Access to Document

10.10116

Cite this

Skinner, S. R., Szarewski, A., Romanowski, B., Garland, S. M., Lazcano-Ponce, E., Salmerón, J., del Rosario-Raymundo, M. R., Verheijen, R. H. M., Quek, S. C., da Silva, D. P., Kitchener, H., Fong, K. L., Bouchard, C., Money, D. M., Illancheran, A., Cruickshank, M. E., Levin, M. J., Chatterjee, A., Stapleton, J. T., ... Dubin, G. (2014). Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. The Lancet, 384, 2213-2227. https://doi.org/10.10116

@article{99062c8d4b304f9ca50bcc618acbaa7b,

title = "Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study",

author = "S.R. Skinner and A. Szarewski and B. Romanowski and S.M. Garland and E. Lazcano-Ponce and J. Salmer{\'o}n and {del Rosario-Raymundo}, M.R. and R.H.M. Verheijen and S.C. Quek and {da Silva}, D.P. and H. Kitchener and K.L. Fong and C. Bouchard and D.M. Money and A. Illancheran and M.E. Cruickshank and M.J. Levin and A. Chatterjee and J.T. Stapleton and W. Quint and M.P. David and D. Meric and K. Hardt and D. Descamps and B. Geeraerts and F. Struyf and G. Dubin",

year = "2014",

doi = "10.10116",

language = "Undefined/Unknown",

volume = "384",

pages = "2213--2227",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

}

Skinner, SR, Szarewski, A, Romanowski, B, Garland, SM, Lazcano-Ponce, E, Salmerón, J, del Rosario-Raymundo, MR, Verheijen, RHM, Quek, SC, da Silva, DP, Kitchener, H, Fong, KL, Bouchard, C, Money, DM, Illancheran, A, Cruickshank, ME, Levin, MJ, Chatterjee, A, Stapleton, JT, Quint, W, David, MP, Meric, D, Hardt, K, Descamps, D, Geeraerts, B, Struyf, F & Dubin, G 2014, 'Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study', The Lancet, vol. 384, pp. 2213-2227. https://doi.org/10.10116

Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. / Skinner, S.R.; Szarewski, A.; Romanowski, B. et al.
In: The Lancet, Vol. 384, 2014, p. 2213-2227.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Efficacy, safety and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

AU - Skinner, S.R.

AU - Szarewski, A.

AU - Romanowski, B.

AU - Garland, S.M.

AU - Lazcano-Ponce, E.

AU - Salmerón, J.

AU - del Rosario-Raymundo, M.R.

AU - Verheijen, R.H.M.

AU - Quek, S.C.

AU - da Silva, D.P.

AU - Kitchener, H.

AU - Fong, K.L.

AU - Bouchard, C.

AU - Money, D.M.

AU - Illancheran, A.

AU - Cruickshank, M.E.

AU - Levin, M.J.

AU - Chatterjee, A.

AU - Stapleton, J.T.

AU - Quint, W.

AU - David, M.P.

AU - Meric, D.

AU - Hardt, K.

AU - Descamps, D.

AU - Geeraerts, B.

AU - Struyf, F.

AU - Dubin, G.

PY - 2014

Y1 - 2014

U2 - 10.10116

DO - 10.10116

M3 - Article

SN - 0140-6736

VL - 384

SP - 2213

EP - 2227

JO - The Lancet

JF - The Lancet

ER -